A5054849148- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory Support and Mechanisms
- Inhalation and Respiratory Drug Delivery
- Asthma and respiratory diseases
- Atrial Fibrillation Management and Outcomes
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Arrhythmias and Treatments
- Respiratory and Cough-Related Research
- Healthcare Policy and Management
- Child Nutrition and Feeding Issues
- Emergency and Acute Care Studies
- Drug-Induced Ocular Toxicity
- Cardiovascular and exercise physiology
- School Health and Nursing Education
- Obstructive Sleep Apnea Research
- Pediatric health and respiratory diseases
- Glaucoma and retinal disorders
- Heart Rate Variability and Autonomic Control
- Chronic Disease Management Strategies
- Ocular Diseases and Behçet’s Syndrome
- Schizophrenia research and treatment
- Food Security and Health in Diverse Populations
Boehringer Ingelheim (United States)
2019-2024
Bayer (United States)
2022
Oregon Health & Science University
2021
Boehringer Ingelheim (Taiwan)
2020
University of Mississippi Medical Center
2020
State Street (United States)
2020
American College of Allergy, Asthma and Immunology
2020
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality associated with substantial economic burden. There lack data regarding COPD outcomes costs in real-world setting, particularly by Global Initiative for Obstructive Lung Disease (GOLD) severity.To (a) characterize commercially insured U.S. population (b) assess prevalence exacerbations, health care resource utilization (HCRU), costs, treatment patterns cohort patients confirmed COPD, overall stratified...
Background Effective stroke prevention with oral anticoagulants (OAC) is recommended for some patients atrial fibrillation (AF). We aimed to describe OAC use by geographical region and type of site in recent‐onset AF enrolled a large global registry. Methods Results Eligible participants were recruited into GLORIA‐AF (Global Registry on Long‐Term Oral Antithrombotic Treatment Patients With Atrial Fibrillation), prospective observational cohort study from 2014 2016 4 international regions:...
Background: Recent studies report a lower mortality rate during treatment with long-acting muscarinic antagonist (LAMA)/long-acting β 2 -agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA/LABA in patients symptomatic chronic obstructive pulmonary disease (COPD) and history of exacerbations. Objective: We compared time to all-cause LAMA/LABA/ICS mild-to-very-severe COPD predominantly low exacerbation risk. Methods: Data were pooled from six randomized controlled trials (TONADO 1/2,...
Background: Reduced physical activity is associated with increased morbidity and mortality in patients COPD. Studies suggest that treatment the long-acting muscarinic antagonist tiotropium β 2 -agonist olodaterol increases exercise capacity. This study assessed effects of a fixed-dose combination (FDC) tiotropium/olodaterol (delivered via Respimat ® ) on functioning stable COPD "real-world setting". Methods: An international, open-label, single-arm, non-interventional conducted nine...
Patients with chronic obstructive pulmonary disease (COPD) show signs of reduced physical activity from the early stages disease, impacting morbidity and mortality. Data suggest treatment tiotropium, a long-acting muscarinic antagonist, olodaterol, ß
Identifying factors influencing peak inspiratory flow (PIF) is essential for aerosol drug delivery in stable patients with chronic obstructive pulmonary disease. While a minimum PIF dry powder inhalers (DPIs) established, acute bronchodilator (BD) effects on remain unknown.
Chronic obstructive pulmonary disease (COPD) is a progressive requiring maintenance therapy. According to the Global Initiative for Obstructive Lung Disease (GOLD) strategy report, bronchodilation with long-acting muscarinic antagonists (LAMAs) and β2-agonists (LABAs), administered via inhalers, currently mainstay of COPD treatment. Combined LAMA/LABA therapies have been shown improve patient health status, lung function breathlessness. Here, we wanted report satisfaction Respimat® Soft...
Background: The Clinical COPD Questionnaire (CCQ) is a simple patient-reported tool to measure clinical control of chronic obstructive pulmonary disease (COPD). Objective: This open-label, single-arm, non-interventional study (NCT03663569) investigated changes in CCQ score during treatment with tiotropium/olodaterol practice. Methods: Data were included from consenting patients, enrolled Bulgaria, Czech Republic, Hungary, Israel, Lithuania, Poland, Romania, Russia, Slovenia, Switzerland and...
Background: We examined the effect of physical position on peak inspiratory flow (PIF) in patients with chronic obstructive pulmonary disease (COPD) using dry powder inhalers (DPIs) low-medium (R2) and/or high (R5) internal resistance.Methods: This prospective study stable, ambulatory spirometry-confirmed COPD evaluated three positions maximal PIF achieved.Participants had 30-90 L/min or 60-90 (R2 DPIs) In-Check™ DIAL.PIF was measured triplicate randomly that might be while their inhaler...
<b>Background:</b> The Clinical COPD Questionnaire (CCQ) is a simple patient-reported tool to measure clinical control of COPD. <b>Aim:</b> This open-label, non-interventional study investigated changes in CCQ score during treatment with tiotropium/olodaterol (Tio/Olo) practice. <b>Methods:</b> Data were included from consenting patients, enrolled 11 countries, who receiving new prescription for Tio/Olo according treating physician. Patients evaluated after 6 weeks. primary analysis was the...
Limited data exist on asthma and chronic obstructive pulmonary disease (COPD) management-major drivers of healthcare resource utilization (HCRU) in the USA. We describe prevalence exacerbation rates, therapeutic interventions, HCRU for and/or COPD within a large, integrated system. Patients with asthma, COPD, + were identified from retrospective electronic health record (2016-2018) >1.7 million patients. Descriptive analysis frequencies, pharmacotherapies, was performed. Time-to-event time...
Rationale: In patients with COPD, inhaler experience may affect compliance and therefore therapeutic success. Two large non-interventional studies (NIS SPIRIT OTIVACTO), including more than 9,000 in total, investigated success (primary endpoint, surrogate for physical functioning) patient satisfaction (secondary endpoints) tiotropium/olodaterol (T/O) delivered via Respimat. This analysis assessed inhalation handling of the Respimat inhaler.
<b>Background:</b> Peak inspiratory flow (PIF) informs dry powder inhaler (DPI) choice. Little is known about modifiable factors affecting PIF. <b>Aim:</b> To examine the impact of physical position on PIF in stable COPD. <b>Methods:</b> We enrolled individuals with spirometry-confirmed COPD, using DPI, and free recent exacerbation. For eligibility, participants must have 30-90 L/min for high resistance (R5, Handihaler<sup>®</sup>) 60-90 low-medium (R2, Diskus<sup>®</sup>,...